NEW YORK, NY — August 27, 2025 — Leads & Copy — Mesoblast Limited (ASX:MSB; Nasdaq:MESO), a global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2025.
The webcast will begin at 6.30pm EDT, Thursday, August 28; 8.30am AEST, Friday, August 29, 2025, and can be accessed via: https://webcast.openbriefing.com/msb-fyr-2025/. The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com.
Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast’s Ryoncil® (remestemcel-L-rknd) is the first FDA-approved mesenchymal stromal cell (MSC) therapy for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older. Please see the full Prescribing Information at www.ryoncil.com.
Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO).
Contact:
Paul Hughes, T: +61 3 9639 6036
Emma Neal, Allison Worldwide, T: +1 603 545 4843, E: emma.neal@allisonworldwide.com
Steve Dabkowski, BlueDot Media, T: +61 419 880 486, E: steve@bluedot.net.au
Source: Mesoblast Limited
